Extreme Levels of Platelet Count in Essential Thrombocythemia: Management and Outcome, Report of Two Cases-Reference-Cited by-同舟云学术

Extreme Levels of Platelet Count in Essential Thrombocythemia: Management and Outcome, Report of Two Cases

Published:2020-06-04 Issue:2 Volume:13 Page:606-610
ISSN:1662-6575
Container-title:Case Reports in Oncology
language:en
Short-container-title:Case Rep Oncol

Author:

Abu-Tineh Mohammad,Yassin Mohamed A.

Abstract

Myeloproliferative neoplasms including essential thrombocythemia (ET) is usually caused by somatic mutations in multiple genes, including the JAK2 (most frequently), CALR gene, and MPL. In rare cases, the disease is caused by other mutations such as THPO or TET2 gene; however, around 10–15% with ET might have triple-negative mutations. Here we present 2 cases of ET who were asymptomatic on diagnoses, but found to have extremely high platelet counts as never reported earlier. The management and treatment plan can be a challenging step. The objective is to draw attention to the early introduction of thrombocytapheresis in the management of such patients given its notable outcomes.

Publisher

S. Karger AG

Subject

Oncology

Reference15 articles.

1. Padmanabhan A, Connelly-Smith L, Aqui N, Balogun RA, Klingel R, Meyer E, et al. Guidelines on the use of therapeutic apheresis in clinical practice – evidence-based approach from the writing committee of the American society for apheresis: the eighth special issue. J Clin Apher. 2019 Jun; 34(3):171–354.

2. Yassin M, Al-Dewik N, ElAyoubi H, Cassinat B. Familial essential thrombocythemia among Qatari tribes. Blood, The Journal of the American Society of Hematology. 2013;122(21):5244.

3. Yassin M, Al-Dewik N, ElAyoubi H, Cassinat B. Efficacy and safety of pegelated interferon alpha2a once monthly compared to once weekly dose in patients with essential thrombocythemia. Blood, The Journal of the American Society of Hematology. 2013;122(21):4054–4054.

4. Hultcrantz M, Wilkes SR, Kristinsson SY, Andersson TM, Derolf ÅR, Eloranta S, et al. Risk and cause of death in patients diagnosed with myeloproliferative neoplasms in Sweden between 1973 and 2005: a population-based study. J Clin Oncol. 2015 Jul 10;33(20):2288–95.

5. Srour SA, Devesa SS, Morton LM, Check DP, Curtis RE, Linet MS, et al. Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001–12. Br J Haematol. 2016 Aug;174(3):382–96.